Prozac pegged as potential 1st treatment for leading cause of blindness (IMAGE)
Caption
Bradley D. Gelfand, PhD, and collaborators have found early evidence that the drug fluoxetine may be effective against atrophic (or “dry”) age-related macular degeneration, a condition that affects nearly 200 million people worldwide. The drug has shown promise in the scientists’ lab tests and animal models, and the researchers bolstered by their results by examining two huge insurance databases encompassing more than 100 million Americans.
Credit
Dan Addison | UVA Communications
Usage Restrictions
May be used to accompany news coverage of the Prozac discovery. All other uses require express written permission from UVA Health.
License
Original content